California has always been where biotech goes to grow up. From the earliest rDNA experiments in San Francisco to the global cell therapy programs running in San Diego today, the state has defined what the life science industry looks like at its most ambitious. That hasn’t changed in 2026, but almost everything around it has.

After two years of correction, consolidation, and cautious optimism, the California biotech hiring market is stabilizing and, in several key areas, accelerating. For companies building teams and professionals navigating their careers, understanding the shape of that recovery matters enormously.

This is BioPhase Solutions’ annual look at the state of biotech hiring across California. We draw on two decades of recruiting experience across San Diego, Los Angeles, and the San Francisco Bay Area, combined with what we’re seeing in real time across our searches, placements, and client conversations. Here’s what 2026 looks like from where we sit.

The Macro Picture: Recovery With Discipline

The biotech industry entered 2026 in a meaningfully different position than it occupied two years ago. The sector-wide layoffs of 2023 and 2024, driven by rising interest rates, a difficult IPO environment, and overhiring during the pandemic boom, have largely run their course. Funding has returned, selectively. M&A activity has picked up sharply, with large pharma spending aggressively to acquire late-stage pipelines rather than build from scratch. And public market sentiment toward biotech has cautiously improved.

But the recovery is not uniform, and it is not returning the industry to 2021 conditions. What has emerged instead is a more disciplined hiring environment, one where companies are thinking carefully about headcount before adding it, where roles are more precisely scoped, and where the bar for candidates has risen alongside the cost of a bad hire.

For candidates, this means searches are taking longer and processes are more rigorous. For companies, it means the talent pool, while more available than it was during the peak, is also more discerning. Experienced professionals who were displaced in the layoffs have had time to reflect on what they want. They are not taking just any offer.

Where the Hiring Is Happening

Not all biotech hiring in California is created equal. The regional picture in 2026 looks like this:

San Diego remains the most active market in the state by sheer volume of companies and open roles. The cluster of clinical and commercial-stage biotechs concentrated in Torrey Pines, Sorrento Valley, and Carmel Mountain Ranch continues to drive consistent demand across research, clinical development, regulatory affairs, and manufacturing. San Diego is particularly active in oncology, gene therapy, and RNA therapeutics, modalities that are all in hiring expansion mode in 2026. The city’s deep talent pool, built over decades, continues to attract and retain scientists who might otherwise be pulled north or east.

The San Francisco Bay Area has rebounded more selectively. The correction hit harder here, where company valuations were highest and hiring most aggressive during the boom years. But South San Francisco, still the densest concentration of biotech square footage in the world, is showing genuine signs of momentum. The Bay Area’s strength in 2026 is concentrated in AI-driven drug discovery, synthetic biology, and platform-stage biotechs that survived the downturn with strong balance sheets and bold science. Compensation here remains the highest in the state, and the competition for computational biology and bioinformatics talent is fiercer than anywhere else in California.

Los Angeles and Orange County represent 2026’s most interesting regional story. What was once seen as a secondary biotech market has matured significantly. Increased venture activity, the growth of the USC and UCLA life science ecosystems, and an influx of established companies expanding south have created genuine momentum. Salaries have risen as the local talent pool has grown more competitive. For companies priced out of Bay Area real estate and compensation expectations, LA has become an increasingly attractive alternative without sacrificing access to strong scientific talent.

The Roles in Highest Demand

Across all three California regions, certain roles consistently top the list of hardest-to-fill positions in 2026.

Computational biologists and bioinformaticians are perhaps the single most contested category in California biotech right now. The intersection of AI, machine learning, and drug discovery has created demand that far outstrips the academic pipeline. Companies are competing not just with each other but with technology companies for this talent, which has driven compensation to levels that would have seemed extraordinary just five years ago.

Regulatory affairs professionals with experience in novel modalities, particularly cell and gene therapy, RNA-based therapeutics, and AI-assisted submissions, are in critically short supply. The FDA’s evolving frameworks have created a premium for professionals who understand both the science and the regulatory pathway well enough to navigate both simultaneously. Senior regulatory talent, especially at the director level and above, is being aggressively recruited and retained.

GMP manufacturing and process development scientists are seeing strong demand as CGT and RNA pipelines mature from clinical to commercial-stage readiness. The biomanufacturing talent pipeline has not kept pace with industry growth, and companies are increasingly hiring ahead of need rather than reactively, a meaningful cultural shift from prior years.

Clinical operations professionals, particularly those with experience in adaptive trial design, decentralized clinical trials, and diversity-focused recruitment strategies, are sought after across both sponsors and CROs. The FDA’s push for more representative trial populations has created new functional specializations within clinical development teams that didn’t exist at scale even three years ago.

Medical affairs and commercial-stage talent is increasingly in demand as more California biotechs approach and cross the commercial threshold. Medical science liaisons, HEOR specialists, and market access professionals represent a category of hiring that was relatively quiet during the lean years but has come back with force in 2026.

The Talent Pool: More Available, More Selective

One of the defining features of the 2026 California biotech talent market is the paradox of availability. There are more experienced life science professionals actively open to new opportunities than at any point since 2020, a direct legacy of the 2023 and 2024 layoff cycles. And yet many of the most qualified candidates are taking longer to commit, conducting more due diligence on prospective employers, and walking away from processes that feel disorganized or disrespectful of their time.

This is a candidate pool that has been burned. Professionals who joined companies on the strength of bold missions and promising pipelines, only to be laid off when the funding environment shifted, are approaching their next move with greater scrutiny. They want to understand the financial runway. They want to meet the team. They want to know that the role they are considering has organizational support and a realistic path forward.

For companies, this means the candidate experience matters more than it used to. Slow processes lose good people. Vague job descriptions attract the wrong applicants. Lowball initial offers, even when later improved, create a credibility gap that is hard to close. The companies winning the talent competition in 2026 are the ones treating recruitment as a strategic function, not an administrative one.

Compensation Trends to Know

Salaries in California biotech have largely held steady coming out of the correction, with modest increases in high-demand specializations. The significant base salary inflation seen in 2021 and 2022 has not returned, but companies that attempted to pull back on compensation during the downturn have found it difficult to attract the talent they need.

A few specific trends worth noting:

Equity has re-entered the conversation in a meaningful way as public market conditions have improved and IPO activity has picked back up. Candidates at growth-stage companies are once again paying close attention to option packages and strike prices, and companies that can tell a compelling equity story have a real advantage.

Sign-on bonuses have become a more common tool, particularly for roles where the candidate is leaving unvested equity behind. For hard-to-fill senior positions, sign-ons in the range of $20,000 to $50,000 are no longer unusual.

Remote and hybrid flexibility remains a meaningful factor in offer decisions, particularly for non-lab roles in regulatory, medical affairs, and clinical development. Companies that have moved to fully on-site mandates for roles that don’t require physical presence are reporting longer time-to-fill and more offer declines.

What It Means for 2026 and Beyond

The California biotech hiring market in 2026 is one of disciplined optimism. The worst of the correction is behind us. The science driving the next decade of medicine, including gene editing, RNA therapeutics, AI-accelerated discovery, and precision oncology, is maturing in California labs right now. The companies pursuing that science are hiring.

But the rules have changed. Talent is available but selective. Compensation must be competitive but is no longer infinitely elastic. Processes must be fast and respectful. And the definition of the right candidate has evolved. Scientific depth matters, but so does the ability to collaborate, communicate, and adapt.

For companies, the opportunity is to hire with intention, building teams that are not just technically capable but strategically positioned for the next stage of growth.

For candidates, the opportunity is to be ready. Keep your resume current, your network active, and your expectations calibrated to a market that rewards preparation and punishes passivity.

BioPhase Solutions has been navigating the California biotech talent market through every cycle since 2004. We have seen the booms and the corrections, and we know what it takes to build great teams and great careers on both sides of the hiring equation.

If 2026 is the year you are ready to move, we would love to be part of the conversation.